查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1697992

慢性鼻竇炎市場 - 全球產業規模、佔有率、趨勢、機會和預測，按疾病表現型、治療類型、配銷通路、地區和競爭細分，2020 年至 2030 年

Chronic Rhinosinusitis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Phenotype, By Treatment Type, By Distribution Channel, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球慢性鼻竇炎市值為 26.2 億美元，預計到 2030 年將達到 39.9 億美元，複合年成長率為 7.23%。全球慢性鼻竇炎市場是一個充滿活力且不斷發展的醫療保健產業，致力於解決普遍存在且持續存在的慢性鼻竇炎 (CRS) 疾病。 CRS 是一種影響鼻腔和鼻竇通道的慢性發炎性疾病，導致鼻塞、臉部疼痛和嗅覺受損等症狀。該市場涵蓋各種藥物、醫療設備和治療方式，旨在緩解症狀、減少發炎並改善受影響個人的整體生活品質。

市場概覽
預測期 2026-2030
2024 年市場規模 26.2億美元
2030年市場規模 39.9 億美元
2025-2030 年複合年成長率 7.23%
成長最快的領域 嗜酸性慢性鼻竇炎
最大的市場 北美洲

全球慢性鼻竇炎市場成長的主要驅動力之一是全球 CRS 發病率的增加。環境污染、過敏和生活方式的改變等因素導致這種疾病的盛行率上升，從而產生了大量尋求有效治療的患者。醫療保健提供者和製藥公司正在積極參與研發工作，推出創新療法，包括生物製劑、皮質類固醇和抗生素，以控制 CRS 並為患者提供長期緩解。

主要市場促進因素

慢性鼻竇炎盛行率上升

主要市場挑戰

治療費用高昂

主要市場趨勢

生物療法

目錄

第 1 章：產品概述

第 2 章：研究方法

第3章：執行摘要

第4章：全球慢性鼻竇炎市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依疾病表現型（非嗜酸性慢性鼻竇炎、嗜酸性慢性鼻竇炎、感染性慢性鼻竇炎、過敏性真菌性鼻竇炎、其他）
    • 依治療類型（醫療器材、藥物、滴鼻劑、類固醇鼻噴劑、手術、其他）
    • 按配銷通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 依疾病表現型
    • 按治療類型
    • 按配銷通路
    • 按地區

第5章：亞太地區慢性鼻竇炎市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依疾病表現型
    • 按治療類型
    • 按配銷通路
    • 按國家
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第6章：歐洲慢性鼻竇炎市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 西班牙
    • 義大利
    • 英國

第7章：北美慢性鼻竇炎市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第8章：南美洲慢性鼻竇炎市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲慢性鼻竇炎市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第10章：市場動態

  • 驅動程式
  • 挑戰

第 11 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 12 章：全球慢性鼻竇炎市場：SWOT 分析

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Lyra Therapeutics
  • Novartis AG
  • Medtronic plc
  • GlaxoSmithKline plc
  • AstraZeneca Plc
  • Sanofi AG
  • Dr. Reddy's Laboratories Ltd.
  • Stryker Corporation
  • Bayer AG
  • Smith & Nephew Plc

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 17457

Global Chronic Rhinosinusitis Market was valued at USD 2.62 Billion in 2024 and is expected to reach USD 3.99 Billion in the forecast period with a CAGR of 7.23% through 2030. The Global Chronic Rhinosinusitis Market is a dynamic and evolving healthcare sector dedicated to addressing the prevalent and persistent condition of chronic rhinosinusitis (CRS). CRS is a chronic inflammatory disease affecting the nasal and sinus passages, leading to symptoms such as nasal congestion, facial pain, and impaired sense of smell. This market encompasses a wide range of pharmaceuticals, medical devices, and treatment modalities aimed at alleviating symptoms, reducing inflammation, and improving the overall quality of life for affected individuals.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.62 Billion
Market Size 2030USD 3.99 Billion
CAGR 2025-20307.23%
Fastest Growing SegmentEosinophilic Chronic Rhinosinusitis
Largest MarketNorth America

One of the primary drivers of growth in the Global Chronic Rhinosinusitis Market is the increasing incidence of CRS worldwide. Factors such as environmental pollutants, allergies, and lifestyle changes contribute to the rising prevalence of this condition, creating a substantial patient pool seeking effective treatments. Healthcare providers and pharmaceutical companies are actively engaged in research and development efforts to introduce innovative therapies, including biologics, corticosteroids, and antibiotics, to manage CRS and provide long-term relief to patients.

Key Market Drivers

Rising Prevalence of Chronic Rhinosinusitis

Chronic Rhinosinusitis (CRS), characterized by prolonged inflammation of the nasal and sinus passages, has seen a notable increase in prevalence globally, significantly impacting the healthcare landscape. This rise is attributed to various factors, including environmental pollution, lifestyle changes, and heightened awareness leading to more frequent diagnoses.

Environmental pollution plays a substantial role in the escalating incidence of CRS. Exposure to air pollutants, particularly particulate matter (PM), has been correlated with increased CRS prevalence and severity. Studies indicate that for each unit increase in PM2.5, there is a 1.89-fold increased risk in the proportion of CRS patients requiring sinus surgery. Additionally, research has shown that long-term exposure to PM2.5 is associated with the development of CRS, underscoring the impact of environmental factors on this condition.

Key Market Challenges

High Treatment Costs

High treatment costs stand out as a significant hindrance in the Global Chronic Rhinosinusitis (CRS) Market, impacting both patients and healthcare systems alike. Chronic Rhinosinusitis, a persistent inflammatory condition of the nasal and sinus passages, requires comprehensive treatment approaches, including diagnostic tests, pharmaceuticals, surgical interventions, and long-term management. The cost associated with these aspects of care can present substantial challenges. One of the primary concerns related to high treatment costs is the financial burden it places on patients. Diagnostic procedures such as computed tomography (CT) scans and magnetic resonance imaging (MRI) can be expensive, and these costs are often not fully covered by insurance plans.

Key Market Trends

Biologic Therapies

Biologic therapies have emerged as a powerful and transformative force in boosting the Global Chronic Rhinosinusitis (CRS) Market. Chronic Rhinosinusitis, characterized by persistent inflammation of the nasal and sinus passages, has historically presented a challenging treatment landscape. However, biologic therapies, including monoclonal antibodies and other targeted drugs, have revolutionized the management of CRS and are driving significant growth in the market.

One of the key factors contributing to the success of biologic therapies is their precision in addressing the underlying inflammatory pathways and immune responses that drive CRS. These therapies are designed to specifically target and inhibit molecules or receptors involved in the inflammatory cascade, thereby reducing symptoms and improving the quality of life for CRS patients. By directly tackling the root causes of inflammation, biologics offer a highly effective and targeted approach to treatment.

Key Market Players

Lyra Therapeutics

Novartis AG

Medtronic plc

GlaxoSmithKline plc

AstraZeneca Plc

Sanofi AG

Dr. Reddy's Laboratories Ltd.

Stryker Corporation

Bayer AG

Smith & Nephew Plc

Report Scope:

In this report, the Global Chronic Rhinosinusitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Rhinosinusitis Market, By Disease Phenotype:

  • Non-Eosinophilic Chronic Rhinosinusitis
  • Eosinophilic Chronic Rhinosinusitis
  • Infectious Chronic Rhinosinusitis
  • Allergic Fungal Rhinosinusitis
  • Others

Chronic Rhinosinusitis Market, By Treatment Type

  • Medical Devices
  • Drugs
  • Nasal Drops
  • Steroid Nasal Sprays
  • Surgery
  • Others

Chronic Rhinosinusitis Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Chronic Rhinosinusitis Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Rhinosinusitis Market.

Available Customizations:

Global Chronic Rhinosinusitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Chronic Rhinosinusitis Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Disease Phenotype (Non-Eosinophilic Chronic Rhinosinusitis, Eosinophilic Chronic Rhinosinusitis, Infectious Chronic Rhinosinusitis, Allergic Fungal Rhinosinusitis, Others)
    • 4.2.2. By Treatment Type (Medical Devices, Drugs, Nasal Drops, Steroid Nasal Sprays, Surgery, Others)
    • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 4.2.4. By Region
    • 4.2.5. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Disease Phenotype
    • 4.3.2. By Treatment Type
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. Asia Pacific Chronic Rhinosinusitis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Phenotype
    • 5.2.2. By Treatment Type
    • 5.2.3. By Distribution Channel
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Chronic Rhinosinusitis Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Disease Phenotype
        • 5.3.1.2.2. By Treatment Type
        • 5.3.1.2.3. By Distribution Channel
    • 5.3.2. India Chronic Rhinosinusitis Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Disease Phenotype
        • 5.3.2.2.2. By Treatment Type
        • 5.3.2.2.3. By Distribution Channel
    • 5.3.3. Australia Chronic Rhinosinusitis Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Disease Phenotype
        • 5.3.3.2.2. By Treatment Type
        • 5.3.3.2.3. By Distribution Channel
    • 5.3.4. Japan Chronic Rhinosinusitis Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Disease Phenotype
        • 5.3.4.2.2. By Treatment Type
        • 5.3.4.2.3. By Distribution Channel
    • 5.3.5. South Korea Chronic Rhinosinusitis Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Disease Phenotype
        • 5.3.5.2.2. By Treatment Type
        • 5.3.5.2.3. By Distribution Channel

6. Europe Chronic Rhinosinusitis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Phenotype
    • 6.2.2. By Treatment Type
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Chronic Rhinosinusitis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Phenotype
        • 6.3.1.2.2. By Treatment Type
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Germany Chronic Rhinosinusitis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Phenotype
        • 6.3.2.2.2. By Treatment Type
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Spain Chronic Rhinosinusitis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Phenotype
        • 6.3.3.2.2. By Treatment Type
        • 6.3.3.2.3. By Distribution Channel
    • 6.3.4. Italy Chronic Rhinosinusitis Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Disease Phenotype
        • 6.3.4.2.2. By Treatment Type
        • 6.3.4.2.3. By Distribution Channel
    • 6.3.5. United Kingdom Chronic Rhinosinusitis Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Disease Phenotype
        • 6.3.5.2.2. By Treatment Type
        • 6.3.5.2.3. By Distribution Channel

7. North America Chronic Rhinosinusitis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Phenotype
    • 7.2.2. By Treatment Type
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Chronic Rhinosinusitis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Phenotype
        • 7.3.1.2.2. By Treatment Type
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Mexico Chronic Rhinosinusitis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Phenotype
        • 7.3.2.2.2. By Treatment Type
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. Canada Chronic Rhinosinusitis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Phenotype
        • 7.3.3.2.2. By Treatment Type
        • 7.3.3.2.3. By Distribution Channel

8. South America Chronic Rhinosinusitis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Phenotype
    • 8.2.2. By Treatment Type
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Chronic Rhinosinusitis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Phenotype
        • 8.3.1.2.2. By Treatment Type
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. Argentina Chronic Rhinosinusitis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Phenotype
        • 8.3.2.2.2. By Treatment Type
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Colombia Chronic Rhinosinusitis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Phenotype
        • 8.3.3.2.2. By Treatment Type
        • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Chronic Rhinosinusitis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Phenotype
    • 9.2.2. By Treatment Type
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Chronic Rhinosinusitis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Phenotype
        • 9.3.1.2.2. By Treatment Type
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Saudi Arabia Chronic Rhinosinusitis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Phenotype
        • 9.3.2.2.2. By Treatment Type
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. UAE Chronic Rhinosinusitis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Phenotype
        • 9.3.3.2.2. By Treatment Type
        • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Chronic Rhinosinusitis Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Lyra Therapeutics
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Novartis AG
  • 14.3. Medtronic plc
  • 14.4. GlaxoSmithKline plc
  • 14.5. AstraZeneca Plc
  • 14.6. Sanofi AG
  • 14.7. Dr. Reddy's Laboratories Ltd.
  • 14.8. Stryker Corporation
  • 14.9. Bayer AG
  • 14.10.Smith & Nephew Plc

15. Strategic Recommendations

16. About Us & Disclaimer